Sei Investments Co. Buys 14,260 Shares of Krystal Biotech, Inc. $KRYS

Sei Investments Co. raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 44.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,570 shares of the company’s stock after purchasing an additional 14,260 shares during the period. Sei Investments Co.’s holdings in Krystal Biotech were worth $12,030,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares during the period. Norges Bank bought a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $70,159,000. William Blair Investment Management LLC boosted its holdings in shares of Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after acquiring an additional 227,038 shares during the period. Janus Henderson Group PLC grew its position in shares of Krystal Biotech by 2,078.9% in the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the last quarter. Finally, UBS Group AG grew its position in shares of Krystal Biotech by 970.8% in the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after purchasing an additional 177,922 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is owned by insiders.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $341.12 on Friday. The stock has a market capitalization of $10.06 billion, a PE ratio of 45.60 and a beta of 0.50. The business has a fifty day moving average price of $339.70 and a two-hundred day moving average price of $296.28. Krystal Biotech, Inc. has a fifty-two week low of $130.50 and a fifty-two week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities analysts expect that Krystal Biotech, Inc. will post 7.31 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on KRYS shares. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup lifted their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. TD Cowen boosted their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Bank of America lifted their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average price target of $360.67.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.